WO2024233949 - REVISION OF GENETIC MATERIAL USING DIRECT REPLACEMENT EDITING
National phase entry:
Publication Number
WO/2024/233949
Publication Date
14.11.2024
International Application No.
PCT/US2024/028906
International Filing Date
10.05.2024
Title **
[English]
REVISION OF GENETIC MATERIAL USING DIRECT REPLACEMENT EDITING
[French]
RÉVISION DE MATÉRIEL GÉNÉTIQUE PAR L'UTILISATION DE L'ÉDITION PAR REMPLACEMENT DIRECT.
Applicants **
TRANSIT THERAPEUTICS, INC.
Inventors
HALPERIN, Schaked, Omer
CHICKERING, Michael
CHAVEZ, Leonard
Priority Data
63/465,799
11.05.2023
US
63/637,313
22.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 9688 | |
| EPO | Filing, Examination, Granting | 150224 | |
| Japan | Filing, Examination, Granting | 5011 | |
| South Korea | Filing, Examination, Granting | 9804 | |
| USA | Filing, Examination, Granting | 37510 |
Total:
212,237
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention provides compositions, systems, and methods for revising nucleic acids. The revision may be accomplished using a fusion protein comprising a nuclease, a ligase, an integrase, or a combination thereof. The nucleic acid revision may include ligation of a donor nucleic acid to a target nucleic acid. The nucleic acid editing may include replacement of a portion of the target nucleic acid with a revising nucleic acid.[French]
L'invention concerne des compositions, des systèmes et des procédés de révision d'acides nucléiques. La révision peut être réalisée à l'aide d'une protéine de fusion comprenant une nucléase, une ligase, une intégrase ou une combinaison de celles-ci. La révision d'acide nucléique peut comprendre la ligature d'un acide nucléique donneur à un acide nucléique cible. L'édition d'acide nucléique peut comprendre le remplacement d'une partie de l'acide nucléique cible par un acide nucléique de révision.